Loading...

Swedish Orphan Biovitrum

DB:B6E
Snowflake Description

Outstanding track record with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
B6E
DB
SEK59B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The last earnings update was 3 days ago. More info.


Add to Portfolio Compare Print
B6E Share Price and Events
7 Day Returns
-11.9%
DB:B6E
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
23.4%
DB:B6E
-10.2%
DE Biotechs
-6%
DE Market
B6E Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Swedish Orphan Biovitrum (B6E) -11.9% -8.1% -12.1% 23.4% 40.1% 147.2%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • B6E outperformed the Biotechs industry which returned -10.2% over the past year.
  • B6E outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
B6E
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Swedish Orphan Biovitrum undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Swedish Orphan Biovitrum to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Swedish Orphan Biovitrum.

DB:B6E Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:B6E
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 22%) (0.01%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:B6E using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Swedish Orphan Biovitrum is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:B6E DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -11,075.60 Analyst x3 -10,257.46
2020 3,713.20 Analyst x3 3,184.88
2021 4,212.73 Analyst x3 3,346.43
2022 5,019.10 Analyst x1 3,692.47
2023 5,267.40 Analyst x1 3,588.89
2024 5,449.13 Est @ 3.45% 3,438.45
2025 5,584.45 Est @ 2.48% 3,263.54
2026 5,685.35 Est @ 1.81% 3,077.08
2027 5,761.14 Est @ 1.33% 2,887.77
2028 5,818.85 Est @ 1% 2,701.25
Present value of next 10 years cash flows SEK18,923.30
DB:B6E DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK5,818.85 × (1 + 0.23%) ÷ (7.98% – 0.23%)
SEK75,272.37
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK75,272.37 ÷ (1 + 7.98%)10
SEK34,943.19
DB:B6E Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK18,923.30 + SEK34,943.19
SEK53,866.49
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK53,866.49 / 294.09
SEK183.16
DB:B6E Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:B6E represents 0.0945x of OM:SOBI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.0945x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 183.16 x 0.0945
€17.31
Value per share (EUR) From above. €17.31
Current discount Discount to share price of €18.90
= -1 x (€18.90 - €17.31) / €17.31
-9.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Swedish Orphan Biovitrum is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Swedish Orphan Biovitrum's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Swedish Orphan Biovitrum's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:B6E PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK8.97
OM:SOBI Share Price ** OM (2019-04-18) in SEK SEK200
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Swedish Orphan Biovitrum.

DB:B6E PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:SOBI Share Price ÷ EPS (both in SEK)

= 200 ÷ 8.97

22.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Swedish Orphan Biovitrum is good value based on earnings compared to the Europe Biotechs industry average.
  • Swedish Orphan Biovitrum is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Swedish Orphan Biovitrum's expected growth come at a high price?
Raw Data
DB:B6E PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 22.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
12.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:B6E PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 22.3x ÷ 12.9%

1.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Swedish Orphan Biovitrum is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Swedish Orphan Biovitrum's assets?
Raw Data
DB:B6E PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK33.49
OM:SOBI Share Price * OM (2019-04-18) in SEK SEK200
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:B6E PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:SOBI Share Price ÷ Book Value per Share (both in SEK)

= 200 ÷ 33.49

5.97x

* Primary Listing of Swedish Orphan Biovitrum.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Swedish Orphan Biovitrum is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Swedish Orphan Biovitrum's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Swedish Orphan Biovitrum has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Swedish Orphan Biovitrum expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Swedish Orphan Biovitrum expected to grow at an attractive rate?
  • Swedish Orphan Biovitrum's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Swedish Orphan Biovitrum's earnings growth is expected to exceed the Germany market average.
  • Swedish Orphan Biovitrum's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:B6E Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:B6E Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 12.9%
DB:B6E Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 10.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:B6E Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:B6E Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 16,406 5,469 4,176 3
2022-12-31 15,941 5,216 3,997 3
2021-12-31 15,791 5,054 4,270 5
2020-12-31 14,761 4,387 3,788 5
2019-12-31 13,016 3,062 3,120 6
DB:B6E Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 9,139 2,090 2,418
2018-09-30 8,443 1,810 2,181
2018-06-30 7,729 1,678 1,881
2018-03-31 7,079 1,287 1,462
2017-12-31 6,511 1,333 1,149
2017-09-30 5,927 1,103 865
2017-06-30 5,497 604 677
2017-03-31 5,327 431 703
2016-12-31 5,204 343 802
2016-09-30 4,727 329 716
2016-06-30 4,341 493 585
2016-03-31 3,636 573 291

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Swedish Orphan Biovitrum's earnings are expected to grow by 12.9% yearly, however this is not considered high growth (20% yearly).
  • Swedish Orphan Biovitrum's revenue is expected to grow by 10.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:B6E Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Swedish Orphan Biovitrum Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:B6E Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 13.92 13.92 13.92 1.00
2022-12-31 13.37 13.37 13.37 1.00
2021-12-31 14.39 18.38 12.45 4.00
2020-12-31 12.78 15.63 11.13 4.00
2019-12-31 10.56 12.52 9.13 5.00
DB:B6E Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 8.97
2018-09-30 8.08
2018-06-30 6.99
2018-03-31 5.43
2017-12-31 4.27
2017-09-30 3.22
2017-06-30 2.52
2017-03-31 2.62
2016-12-31 2.99
2016-09-30 2.67
2016-06-30 2.18
2016-03-31 1.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Swedish Orphan Biovitrum is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Swedish Orphan Biovitrum's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Swedish Orphan Biovitrum has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Swedish Orphan Biovitrum performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Swedish Orphan Biovitrum's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Swedish Orphan Biovitrum has delivered over 20% year on year earnings growth in the past 5 years.
  • Swedish Orphan Biovitrum's 1-year earnings growth exceeds its 5-year average (110.5% vs 68.1%)
  • Swedish Orphan Biovitrum's earnings growth has exceeded the Europe Biotechs industry average in the past year (110.5% vs 18.2%).
Earnings and Revenue History
Swedish Orphan Biovitrum's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Swedish Orphan Biovitrum Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:B6E Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 9,138.89 2,417.80 2,510.74 1,090.42
2018-09-30 8,442.83 2,180.61 2,347.47 990.72
2018-06-30 7,728.83 1,880.61 2,206.47 917.72
2018-03-31 7,078.83 1,461.61 2,136.47 922.72
2017-12-31 6,510.83 1,148.61 2,084.47 907.72
2017-09-30 5,927.34 864.64 2,006.26 936.59
2017-06-30 5,497.34 676.64 1,963.26 901.59
2017-03-31 5,327.34 702.64 1,861.26 857.59
2016-12-31 5,204.34 801.64 1,776.26 777.59
2016-09-30 4,726.87 715.91 1,632.86 654.37
2016-06-30 4,340.87 584.91 1,538.86 595.37
2016-03-31 3,635.87 290.91 1,462.86 519.37
2015-12-31 3,227.87 64.91 1,344.86 513.37
2015-09-30 3,118.98 59.17 1,263.49 528.49
2015-06-30 2,999.98 108.17 1,177.49 499.49
2015-03-31 2,898.98 136.17 1,094.49 505.49
2014-12-31 2,606.98 -267.83 1,031.49 500.49
2014-09-30 2,512.69 -263.46 1,006.56 453.39
2014-06-30 2,363.99 -372.86 971.36 475.49
2014-03-31 2,221.19 -409.76 932.96 463.49
2013-12-31 2,176.69 -92.96 895.56 455.69
2013-09-30 2,037.86 -222.18 831.08 451.95
2013-06-30 1,984.46 -211.08 802.78 435.95
2013-03-31 1,944.96 -267.88 794.08 423.45
2012-12-31 1,923.16 -100.88 798.88 401.65
2012-09-30 1,887.63 53.63 825.02 407.39
2012-06-30 1,870.83 60.53 818.72 407.59

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Swedish Orphan Biovitrum has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Swedish Orphan Biovitrum used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Swedish Orphan Biovitrum has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Swedish Orphan Biovitrum's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Swedish Orphan Biovitrum has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Swedish Orphan Biovitrum's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Swedish Orphan Biovitrum's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Swedish Orphan Biovitrum's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Swedish Orphan Biovitrum's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Swedish Orphan Biovitrum's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2207.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Swedish Orphan Biovitrum Company Filings, last reported 3 months ago.

DB:B6E Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 9,040.10 2.99 2,998.74
2018-09-30 8,499.00 5.00 2,488.00
2018-06-30 7,851.00 7.00 2,306.00
2018-03-31 7,215.00 6.00 1,750.00
2017-12-31 6,700.52 5.04 1,478.50
2017-09-30 6,352.00 505.00 1,758.00
2017-06-30 5,967.00 504.00 1,189.00
2017-03-31 5,592.00 504.00 1,032.00
2016-12-31 5,364.97 502.22 785.79
2016-09-30 5,370.00 504.00 824.00
2016-06-30 5,247.00 504.00 770.00
2016-03-31 5,016.00 803.00 1,108.00
2015-12-31 4,660.21 800.34 903.66
2015-09-30 4,640.00 822.00 914.00
2015-06-30 4,672.00 821.00 763.00
2015-03-31 4,645.00 819.00 682.00
2014-12-31 4,522.87 811.78 519.15
2014-09-30 4,532.90 817.10 611.30
2014-06-30 4,475.40 816.70 503.20
2014-03-31 4,443.10 795.80 573.70
2013-12-31 4,769.24 797.60 445.10
2013-09-30 4,774.60 795.80 449.30
2013-06-30 4,826.70 801.30 438.10
2013-03-31 4,840.10 800.70 401.20
2012-12-31 4,838.00 591.55 456.95
2012-09-30 4,986.40 614.30 319.20
2012-06-30 5,040.40 613.70 350.00
  • Swedish Orphan Biovitrum's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (16.7% vs 0% today).
  • Debt is well covered by operating cash flow (69885.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 58.2x coverage).
X
Financial health checks
We assess Swedish Orphan Biovitrum's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Swedish Orphan Biovitrum has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Swedish Orphan Biovitrum's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Swedish Orphan Biovitrum dividends. Estimated to be 0% next year.
If you bought €2,000 of Swedish Orphan Biovitrum shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Swedish Orphan Biovitrum's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Swedish Orphan Biovitrum's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:B6E Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:B6E Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Swedish Orphan Biovitrum has not reported any payouts.
  • Unable to verify if Swedish Orphan Biovitrum's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Swedish Orphan Biovitrum's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Swedish Orphan Biovitrum has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Swedish Orphan Biovitrum's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Swedish Orphan Biovitrum's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Swedish Orphan Biovitrum afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Swedish Orphan Biovitrum has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Swedish Orphan Biovitrum's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Guido Oelkers
COMPENSATION SEK16,426,514
AGE 53
TENURE AS CEO 1.9 years
CEO Bio

Dr. Guido Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. Dr. Oelkers serves as Group Chief Executive of BSN medical Inc. He served as the Chief Executive Officer of BSN medical GmbH. Dr. Oelkers served as the Chief Executive Officer and President of Gambro AB. He served as an Executive Vice President of Commercial Operations at Nycomed SICAR S.C.A. since September 1, 2008. He served as the Chief Executive Officer of A. Menarini Asia-Pacific Holdings Pte. Ltd. (alternative name Invida Pharmaceutical Holdings Pte. Ltd.). He served as an Executive Vice President and Global Head of Healthcare. He has been working in the pharmaceutical and healthcare industry since 1984. In his work at Hoechst AG, he was exposed to a wide array of interdisciplinary managerial roles including the evaluations of NCEs in conjunction with R&D at the head office of Hoechst AG. He has gained extensive General Management experience in the pharmaceutical industry as head of various country organizations of Aventis Pharma and preceding entities in PRC, Indonesia and New Zealand from 1994 to 2000. From 2000 to August 2006, he worked for DKSH in Asia Pacific. He has been a Director at Meda AB since May 7, 2014. He has been a Member of Supervisory Board at Sartorius Aktiengesellschaft since November 6, 2017. He joined various graduate programmes in Economics at London School of Economics & Political Science. He is an Economist by training. He holds a PhD in Strategic Management from University of South Australia, Master of Economics from Southbank University London and Degree in Business Administration (Dipl-Betriebswirt) from German University, Mainz, Germany.

CEO Compensation
  • Insufficient data for Guido to compare compensation growth.
  • Guido's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Swedish Orphan Biovitrum management team in years:

1.1
Average Tenure
51
Average Age
  • The average tenure for the Swedish Orphan Biovitrum management team is less than 2 years, this suggests a new team.
Management Team

Guido Oelkers

TITLE
CEO & President
COMPENSATION
SEK16M
AGE
53
TENURE
1.9 yrs

Henrik Stenqvist

TITLE
Chief Financial Officer
AGE
51
TENURE
0.8 yrs

Anne de Jonge Schuermans

TITLE
Head of Technical Operations
AGE
46
TENURE
0.5 yrs

Paula Treutiger

TITLE
Head of Communications & Investor Relations
AGE
51
TENURE
0.3 yrs

Torbjörn Hallberg

TITLE
General Counsel & Head of Legal Affairs
AGE
49
TENURE
1.3 yrs

Fredrik Wetterlundh

TITLE
Head of Human Resources
AGE
52
TENURE
1 yrs

Annika Muskantor

TITLE
Head of Global Supply Chain
AGE
52

Krassimir Mitchev

TITLE
VP & Medical Therapeutic Area Head of Haemophilia
TENURE
5.5 yrs

Philip Wood

TITLE
Head of Haemophilia
AGE
50
TENURE
5.4 yrs

Bruce Faulkner-Dunkley

TITLE
Global Head of L&OD
Board of Directors Tenure

Average tenure and age of the Swedish Orphan Biovitrum board of directors in years:

7
Average Tenure
62.5
Average Age
  • The tenure for the Swedish Orphan Biovitrum board of directors is about average.
Board of Directors

Sven Björklund

TITLE
Chairman
COMPENSATION
SEK1M
AGE
62
TENURE
2.9 yrs

Hans Wigzell

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
SEK158K
AGE
80
TENURE
18.3 yrs

Lennart Johansson

TITLE
Director
COMPENSATION
SEK522K
AGE
63
TENURE
9 yrs

Annette Clancy

TITLE
Director
COMPENSATION
SEK510K
AGE
64
TENURE
4.9 yrs

Ralf Pettersson

TITLE
Member of Scientific Advisory Board

Stefan Del Prato

TITLE
Member of Scientific Advisory Board

Stephen O'Rahilly

TITLE
Member of Scientific Advisory Board

Jonathan Sanders Arch

TITLE
Member of Scientific Advisory Board

Bo-Gunnar Rosenbrand

TITLE
Employee Representative Director
AGE
55
TENURE
13.3 yrs

Pia Axelson

TITLE
Employee Representative Director
AGE
56
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Dec 18 Buy Bo-Gunnar Rosenbrand Individual 03. Dec 18 03. Dec 18 76 €19.18 €1,458
22. Nov 18 Buy Milan Zdravkovic Individual 22. Nov 18 22. Nov 18 8,820 €19.17 €167,869
16. Nov 18 Buy Torbjörn Hallberg Individual 16. Nov 18 16. Nov 18 3,500 €18.26 €63,911
15. Nov 18 Buy Norbert Oppitz Individual 15. Nov 18 15. Nov 18 10,000 €18.50 €184,987
15. Nov 18 Buy Guido Oelkers Individual 14. Nov 18 14. Nov 18 49,000 €18.50 €904,711
24. Aug 18 Buy Philip Wood Individual 22. Aug 18 22. Aug 18 9,268 €25.39 €235,272
23. Aug 18 Buy Bo-Gunnar Rosenbrand Individual 22. Aug 18 22. Aug 18 228 €25.39 €5,788
19. Jun 18 Buy Bo-Gunnar Rosenbrand Individual 13. Jun 18 13. Jun 18 79 €18.52 €1,463
X
Management checks
We assess Swedish Orphan Biovitrum's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Swedish Orphan Biovitrum has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren’s contracture and Peyronie’s disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Details
Name: Swedish Orphan Biovitrum AB (publ)
B6E
Exchange: DB
Founded:
SEK5,626,020,360
294,091,483
Website: http://www.sobi.com
Address: Swedish Orphan Biovitrum AB (publ)
Tomtebodavägen 23A,
Solna,
Stockholm County, 112 76,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM SOBI Class A Shares OMX Nordic Exchange Stockholm SE SEK 15. Sep 2006
OTCPK BIOV.F Class A Shares Pink Sheets LLC US USD 15. Sep 2006
DB B6E Class A Shares Deutsche Boerse AG DE EUR 15. Sep 2006
LSE 0MTD Class A Shares London Stock Exchange GB SEK 15. Sep 2006
BATS-CHIXE SOBIS Class A Shares BATS 'Chi-X Europe' GB SEK 15. Sep 2006
Number of employees
Current staff
Staff numbers
902
Swedish Orphan Biovitrum employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 20:57
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/04/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.